Michael D. Prados

TL;DR: The most strongly associated SNP, rs55705857, remained highly significant after individual adjustment for the other top six SNPs and two previously published SNPs, and is consistently modeled as a microRNA.

TL;DR: The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas, with generally well tolerated results.

TL;DR: The most impactful biomarker for posterior fossa ependymoma is molecular subgroup affiliation, independent of other demographic or treatment variables, with the survival rates being particularly poor for subtotally resected EPN_PFA, even with adjuvant radiation therapy.

TL;DR: Evidence is provided that with established dosing, cilengitide is adequately delivered to the tumor, although as a single agent, efficacy in recurrent glioblastoma is modest, however, these results demonstrating drug delivery to tumor do support continued investigation of this agent as preliminary results from recent studies combining cilENGitide with cytotoxic therapies are promising.

TL;DR: Despite the limited number of responses, 6-month PFS and median survival reached or exceeded the previously reported values for patients undergoing chemotherapy for recurrent glioblastoma.